WHO advises against use of COVID-19 survivors' plasma to treat patients battling virus

Experts at the World Health Organization recommended Tuesday against using blood plasma from people who have recovered from COVID-19 as a treatment for patients with the illness, saying evidence has not shown the costly, time-consuming transfusions to be effective in preventing severe illness or death.

RELATED: WHO: Kids in 5-14 age group account for Europe's highest COVID-19 rates

The guidance against the use of convalescent plasma, a component of blood that is rich in antibodies, was published in the British Medical Journal based on results from 16 trials involving more than 16,000 patients with varying degrees of coronavirus infection, WHO said.

"Despite its initial promise, current evidence shows that it does not improve survival nor reduce the need for mechanical ventilation, and it is costly and time-consuming to administer," the U.N. health agency said in announcing the recommendation of an international group of experts on guideline development.

RELATED: Omicron variant may be less dangerous than delta, US health officials say

"As such, the WHO makes a strong recommendation against the use of convalescent plasma in patients with non-severe illness, and a recommendation against its use in patients with severe and critical illness, except in the context of a randomized controlled trial," WHO said.

The group of experts said in an 81-page study that there was "no clear benefit for critical outcomes" such as the need for mechanical ventilation - breathing machines - or deaths of COVID-19 patients.

WHO previously weighed in on other COVID-19 treatments, such as recommending some steroids for patients with severe or critical cases, and advising against the use of the anti-parasite medication ivermectin and the malaria drug hydroxychloroquine.